Omnicell, Inc. (OMCL): Price and Financial Metrics


Omnicell, Inc. (OMCL): $115.37

1.62 (+1.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OMCL POWR Grades


  • Growth is the dimension where OMCL ranks best; there it ranks ahead of 83.97% of US stocks.
  • OMCL's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • OMCL ranks lowest in Momentum; there it ranks in the 16th percentile.

OMCL Stock Summary

  • With a price/earnings ratio of 76, OMNICELL Inc P/E ratio is greater than that of about 90.69% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for OMCL is currently 25.52, higher than 76.31% of US stocks with positive operating cash flow.
  • Over the past twelve months, OMCL has reported earnings growth of 151.95%, putting it ahead of 86.91% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to OMNICELL Inc, a group of peers worth examining would be RGEN, PUBM, NCR, ECOM, and ICHR.
  • OMCL's SEC filings can be seen here. And to visit OMNICELL Inc's official web site, go to www.omnicell.com.

OMCL Valuation Summary

  • In comparison to the median Technology stock, OMCL's price/sales ratio is 30.19% higher, now standing at 6.9.
  • Over the past 243 months, OMCL's price/earnings ratio has gone up 131.6.
  • Over the past 243 months, OMCL's EV/EBIT ratio has gone up 105.1.

Below are key valuation metrics over time for OMCL.

Stock Date P/S P/B P/E EV/EBIT
OMCL 2021-09-01 6.9 6.5 114.9 85.8
OMCL 2021-08-31 6.8 6.4 113.0 84.4
OMCL 2021-08-30 6.9 6.4 113.3 84.6
OMCL 2021-08-27 7.0 6.6 115.5 86.3
OMCL 2021-08-26 6.8 6.4 112.5 84.0
OMCL 2021-08-25 6.9 6.4 113.6 84.8

OMCL Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 188.25%.
  • Its 2 year cash and equivalents growth rate is now at 137.77%.
  • Its 2 year revenue growth rate is now at 23.52%.
OMCL's revenue has moved up $324,811,000 over the prior 34 months.

The table below shows OMCL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,132.018 231.809 77.849
2021-09-30 1,070.186 248.625 80.245
2021-06-30 987.483 242.323 59.733
2021-03-31 914.365 218.054 35.01
2020-12-31 892.208 185.87 32.194
2020-09-30 891.298 144.242 37.912

OMCL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OMCL has a Quality Grade of C, ranking ahead of 58.08% of graded US stocks.
  • OMCL's asset turnover comes in at 0.534 -- ranking 55th of 83 Computers stocks.
  • STRM, PBI, and CERN are the stocks whose asset turnover ratios are most correlated with OMCL.

The table below shows OMCL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.534 0.485 0.087
2021-03-31 0.550 0.466 0.054
2020-12-31 0.595 0.463 0.052
2020-09-30 0.658 0.464 0.064
2020-06-30 0.734 0.473 0.105
2020-03-31 0.752 0.486 0.148

OMCL Price Target

For more insight on analysts targets of OMCL, see our OMCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.50 Average Broker Recommendation 1.55 (Moderate Buy)

OMCL Stock Price Chart Interactive Chart >

Price chart for OMCL

OMCL Price/Volume Stats

Current price $115.37 52-week high $187.29
Prev. close $113.75 52-week low $104.32
Day low $113.39 Volume 10,030,500
Day high $117.19 Avg. volume 530,700
50-day MA $112.52 Dividend yield N/A
200-day MA $144.83 Market Cap 5.10B

Omnicell, Inc. (OMCL) Company Bio


Omnicell provides automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company was founded in 1992 and is based in Mountain View, California.


OMCL Latest News Stream


Event/Time News Detail
Loading, please wait...

OMCL Latest Social Stream


Loading social stream, please wait...

View Full OMCL Social Stream

Latest OMCL News From Around the Web

Below are the latest news stories about OMNICELL Inc that investors may wish to consider to help them evaluate OMCL as an investment opportunity.

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

Style Box ETF report for SLYG

Yahoo | February 23, 2022

Omnicell Delivers Solid Q4 Results On record Bookings; Issues Guidance

Omnicell (OMCL) delivered solid fourth-quarter and full-year results characterized by record bookings and supported by robust customer demand. OMCL shares fell 4.40% to close at $147.60 on February 14. Omnicell is a U.S. company that provides medication management automation solutions. It also offers adherence tools to healthcare systems and pharmacies. Omnicell Earnings Revenue in the quarter was up 25% year-over-year to $311.7 million, beating consensus estimates of $311.07 million. The increase is attributed to the strong demand for the company's medication management adherence automation solutions. The company also benefited from the acquisition of FDS Amplicare. Full-year revenue was up 27% year-over-year to $1.13 billion.

Payal Gupta on TipRanks | February 15, 2022

Omnicell (OMCL) Receives a Buy from Berenberg Bank

Berenberg Bank analyst Dev Weerasuriya maintained a Buy rating on Omnicell (OMCL – Research Report) today and set a price target of $176.00. The company's shares closed last Monday at $147.60. According to TipRanks.com, Weerasuriya is ranked #5513 out of 7791 analysts. Omnicell has an analyst consensus of Strong Buy, with a price target consensus of $202.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $187.29 and a one-year low of $119.76. Currently, Omnicell has an average volume of 316.8K. Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock.

Brian Anderson on TipRanks | February 15, 2022

Omnicell''s Q4 Earnings In Line With Expectations, Issues Mixed FY22 Guidance

Omnicell Inc''s (NASDAQ: OMCL ) Q4 sales increased 25% Y/Y to $311.0 million , compared to the consensus of $311 million. The increase reflects strong demand for Omnicell''s medication management adherence automation solutions and the contribution of revenues from the acquisition of RxInnovation Inc , operating as FDS Amplicare . The company posted an adjusted EPS of $0.92 in line with the consensus. Adjusted EBITDA was $52.0 million, compared to $51.6 million in Q4 … Full story available on Benzinga.com

Benzinga | February 15, 2022

Omnicell stock plunges as 2022 earnings guidance disappoints (NASDAQ:OMCL)

Recording the biggest intraday decline since March 2020, the shares of Omnicell <> have approached an eight-month low after the med-tech company set its 2022 earnings guidance…

Seeking Alpha | February 15, 2022

Read More 'OMCL' Stories Here

OMCL Price Returns

1-mo 6.30%
3-mo -8.63%
6-mo -30.82%
1-year N/A
3-year 33.72%
5-year 173.07%
YTD -36.06%
2021 50.34%
2020 46.87%
2019 33.44%
2018 26.27%
2017 43.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5765 seconds.